EP 1673096 A1 20060628 - USE OF A VITAMIN D3 ANALOGUE FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

Title (en)

USE OF A VITAMIN D3 ANALOGUE FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

Title (de)

VERWENDUNG EINES VITAMIN-D3-ANALOGONS ZUR BEHANDLUNG VON BENIGNER PROSTATAHYPERPLASIE

Title (fr)

UTILISATION D'UN ANALOGUE DE VITAMINE D3 POUR LE TRAITEMENT DE L'HYPERPLASIE PROSTATIQUE BENIGNE

Publication

EP 1673096 A1 20060628 (EN)

Application

EP 04765598 A 20040924

Priority

EP 2004010760 W 20040924
GB 0322395 A 20030924
GB 0325598 A 20031103
GB 0416876 A 20040729

Abstract (en)

[origin: FR2859910A1] The use of 1alpha -fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol (I) or its salt or ester (I') is claimed in the production of medicaments for the treatment and/or prophylaxis of benign prostatic hypertrophy (BPH), (I)/(I') optionally being used in combination with a second anti-BPH agent (II). The use of 1alpha -fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol (I) or its salt or ester (I') is claimed in the production of medicaments for the treatment and/or prophylaxis of benign prostatic hypertrophy (BPH), (I)/(I') optionally being used in combination with a second anti-BPH agent (II) (administered separately, sequentially or simultaneously in the same formulation or a different formulation). Independent claims are included for: (1) corresponding formulations for treating BPH; and (2) pharmaceutical formulations (A) (with no restriction on use) comprising (I) dissolved in fractionated coconut oil, optionally together with preservative(s). ACTIVITY : Cytostatic; Uropathic; Antipsoriatic; Antiseborrheic; Dermatological; Osteopathic. MECHANISM OF ACTION : Apoptosis inducer.

IPC 1-7

A61K 31/593; A61P 13/08; A61P 13/10

IPC 8 full level

A61K 31/59 (2006.01); A61K 31/593 (2006.01); A61K 45/06 (2006.01); A61P 13/08 (2006.01); A61P 13/10 (2006.01)

CPC (source: EP)

A61K 31/59 (2013.01); A61K 31/593 (2013.01); A61K 45/06 (2013.01); A61P 3/02 (2017.12); A61P 13/02 (2017.12); A61P 13/04 (2017.12); A61P 13/08 (2017.12); A61P 13/10 (2017.12); A61P 29/00 (2017.12); A61P 43/00 (2017.12)

C-Set (source: EP)

Citation (search report)

See references of WO 2005027923A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

FR 2859910 A1 20050325; FR 2859910 B1 20060428; BE 1016292 A3 20060704; BR PI0404050 A 20050614; CH 698144 B1 20090529; CN 100488511 C 20090520; CN 1615891 A 20050518; EA 010240 B1 20080630; EA 200401100 A1 20050428; EP 1673096 A1 20060628; HK 1085373 A1 20060825; JP 2007506699 A 20070322; JP 2009035559 A 20090219; NL 1027109 A1 20050329; NL 1027109 C2 20050503; NZ 535531 A 20060331; WO 2005027923 A1 20050331

DOCDB simple family (application)

FR 0410073 A 20040923; BE 200400472 A 20040924; BR PI0404050 A 20040922; CH 15532004 A 20040922; CN 200410080081 A 20040924; EA 200401100 A 20040923; EP 04765598 A 20040924; EP 2004010760 W 20040924; HK 05108113 A 20050916; JP 2006527365 A 20040924; JP 2008209429 A 20080818; NL 1027109 A 20040924; NZ 53553104 A 20040923